Cardiol Therapeutics (CRDL) Price & Analysis

Compare

608 Followers

CRDL Stock Chart & Stats

$0.96

-$0.03(-2.19%)

At close: Jan 08 4:00 PM EST

$0.96

-$0.03(-2.19%)

Day’s Range― - ―

52-Week Range$0.77 - $1.59

Previous Close$1.33

Volume248.87K

Average Volume (3M)701.45K

Market Cap

$103.67M

Enterprise Value$134.86M

Total Cash (Recent Filing)$11.62M

Total Debt (Recent Filing)$134.20K

Price to Earnings (P/E)―

Beta1.48

Next Earnings

Apr 01, 2026

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding98,855,720

10 Day Avg. Volume564,759

30 Day Avg. Volume701,452

Financial Highlights & Ratios

PEG Ratio-0.23

Price to Book (P/B)5.35

Price to Sales (P/S)0.00

P/FCF Ratio-5.28

Enterprise Value/Market Cap1.30

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.29K

Enterprise Value/Ebitda-3.75

Forecast

1Y Price Target

$8.25

Price Target Upside759.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe trial results demonstrated improved multiple cardiac magnetic resonance imaging (CMR) measures of myocardial recovery, heart size, and function following 12 weeks of treatment.

Drug DevelopmentThe results from ARCHER study add clinical evidence to the anti-inflammatory effect of CaridolRx and enhances confidence in the ongoing Phase III MAVERIC study for the drug in recurrent pericarditis.

Financial PositionThe company announced an $11.4M capital raise in October, extending the cash runway into 3Q27.

Bears Say

Cardiol Therapeutics News

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Toronto, Ontario, December 1st, 2025, FinanceWire Phase II ARCHER trial showed a significant reduction in left ventricular (LV)...

5d ago

CRDL

Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential

Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Cardiol Therapeutics. The associated price target...

5d ago

CRDL

Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™

Cardiol Therapeutics ( ($TSE:CRDL) ) has provided an update. On December 1, 2025, Cardiol Therapeutics announced new data...

5d ago

CRDL

Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress

Cardiol Therapeutics Inc. ( ($CRDL) ) has released its Q3 earnings. Here is a breakdown of the information...

9d ago

CRDL

Cardiol Therapeutics: Promising Pipeline and Financial Stability Support Buy Rating

Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Cardiol Therapeutics, retaining the price target of...

22d ago

CRDL

Cardiol Therapeutics Reports Q3 2025 Financial Results Amidst Cash Decrease

Cardiol Therapeutics ( ($TSE:CRDL) ) just unveiled an update. Cardiol Therapeutics Inc. released its condensed interim consolidated financial...

22d ago

CRDL

Cardiol Therapeutics Secures U.S. Patent for Heart Drugs

The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). On November 13, 2025, Cardiol Therapeutics announced...

23d ago

CRDL

Cardiol Therapeutics to Present Promising ARCHER Trial Results at ESC Meeting

Cardiol Therapeutics ( ($TSE:CRDL) ) has provided an update. Cardiol Therapeutics announced that the full data from its...

1M ago

CRDL

Cardiol Therapeutics Raises $16 Million Through Recent Securities Distribution

The latest update is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardiol Therapeutics Inc. recently completed an exempt...

1M ago

CRDL

Cardiol Therapeutics’ Phase-3 Trial: A Potential Game-Changer in Recurrent Pericarditis Treatment

Cardiol Therapeutics Inc. (($CRDL)) announced an update on their ongoing clinical study. Cardiol Therapeutics Inc. is conducting a...

1M ago

CRDL

Cardiol Therapeutics trading resumes

17:05 EDT Cardiol Therapeutics (CRDL) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

2M ago

CRDL

Cardiol Therapeutics trading halted, news pending

16:14 EDT Cardiol Therapeutics (CRDL) trading halted, news pending Published first on TheFly – the ultimate source for...

2M ago

CRDL

Roth bullish on Cardiol, says trial results enough to attract larger partner

Keeping a Buy rating on Cardiol Therapeutics (CRDL), Roth Capital notes that top-line results for the ARCHER for...

4M ago

CRDL

Cardiol ARCHER study not statistically significant, says Canaccord

Canaccord says that while the top-line results from Cardiol Therapeutics (CRDL)’ Phase II ARCHER trial in patients with...

4M ago

CRDL

CRDL FAQ

What was Cardiol Therapeutics’s price range in the past 12 months?

Cardiol Therapeutics lowest stock price was $0.77 and its highest was $1.59 in the past 12 months.

What is Cardiol Therapeutics’s market cap?

Cardiol Therapeutics’s market cap is $103.67M.

When is Cardiol Therapeutics’s upcoming earnings report date?

Cardiol Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 116 days.

How were Cardiol Therapeutics’s earnings last quarter?

Cardiol Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.086 earnings per share for the quarter, missing the consensus estimate of -$0.072 by -$0.014.

Is Cardiol Therapeutics overvalued?

According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cardiol Therapeutics pay dividends?

Cardiol Therapeutics does not currently pay dividends.

What is Cardiol Therapeutics’s EPS estimate?

Cardiol Therapeutics’s EPS estimate is -0.08.

How many shares outstanding does Cardiol Therapeutics have?

Cardiol Therapeutics has 98,855,720 shares outstanding.

What happened to Cardiol Therapeutics’s price movement after its last earnings report?

Cardiol Therapeutics reported an EPS of -$0.086 in its last earnings report, missing expectations of -$0.072. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Cardiol Therapeutics?

Currently, no hedge funds are holding shares in CRDL

Cardiol Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-271.56%

Trailing 12-Months

Asset Growth

-24.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics (CRDL) Earnings & Revenues

Historic Earnings Reports

CRDL Stock 12 Month Forecast

Average Price Target

$8.25

▲(759.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.95,1.646153846153846,2.3423076923076924,3.0384615384615383,3.7346153846153847,4.430769230769231,5.126923076923077,5.823076923076924,6.51923076923077,7.215384615384616,7.911538461538463,8.607692307692309,9.303846153846154,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.95,1.5115384615384615,2.073076923076923,2.6346153846153846,3.1961538461538463,3.7576923076923077,4.319230769230769,4.880769230769231,5.4423076923076925,6.003846153846154,6.565384615384615,7.126923076923077,7.688461538461539,{"y":8.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.95,1.3384615384615384,1.726923076923077,2.1153846153846154,2.503846153846154,2.8923076923076922,3.2807692307692307,3.6692307692307695,4.0576923076923075,4.446153846153846,4.834615384615384,5.223076923076923,5.611538461538462,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >